{"id":"https://openalex.org/W2051652916","doi":"https://doi.org/10.4161/mabs.23452","title":"Novel asymmetrically engineered antibody Fc variant with superior Fc\u03b3R binding affinity and specificity compared with afucosylated Fc variant","display_name":"Novel asymmetrically engineered antibody Fc variant with superior Fc\u03b3R binding affinity and specificity compared with afucosylated Fc variant","alternate_titles":[],"publication_year":2013,"publication_date":"2013-03-01","ids":{"openalex":"https://openalex.org/W2051652916","doi":"https://doi.org/10.4161/mabs.23452","mag":"2051652916","pmid":"https://pubmed.ncbi.nlm.nih.gov/23406628","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3893233"},"language":"en","primary_location":{"id":"doi:10.4161/mabs.23452","doi":"https://doi.org/10.4161/mabs.23452","is_oa":true,"landing_page_url":"https://doi.org/10.4161/mabs.23452","pdf_url":"https://www.tandfonline.com/doi/pdf/10.4161/mabs.23452?needAccess=true","source":{"id":"https://openalex.org/S169123381","display_name":"mAbs","issn_l":"1942-0862","issn":["1942-0862","1942-0870"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315740","host_organization_name":"Landes Bioscience","host_organization_lineage":["https://openalex.org/P4310315740"],"host_organization_lineage_names":["Landes Bioscience"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"mAbs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2051652916"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.tandfonline.com/doi/pdf/10.4161/mabs.23452?needAccess=true","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5056612739","display_name":"Futa Mimoto","orcid":"https://orcid.org/0000-0001-6972-9631","observed_orcids":["https://orcid.org/0000-0001-6972-9631"]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Futa Mimoto","raw_affiliation_strings":["Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan","Chugai Pharmaceutical Co., Ltd","Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Chugai Pharmaceutical Co., Ltd","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Tokyo, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005341632","display_name":"Tomoyuki Igawa","orcid":"https://orcid.org/0000-0003-0097-8220","observed_orcids":["https://orcid.org/0000-0003-0097-8220"]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Tomoyuki Igawa","raw_affiliation_strings":["Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","Chugai Pharmaceutical Co., Ltd","Research Division","Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Chugai Pharmaceutical Co., Ltd","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Research Division","institution_ids":[]},{"raw_affiliation_string":"Tokyo, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086883349","display_name":"Taichi Kuramochi","orcid":"https://orcid.org/0000-0001-7242-7124","observed_orcids":["https://orcid.org/0000-0001-7242-7124"]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Taichi Kuramochi","raw_affiliation_strings":["Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","Chugai Pharmaceutical Co., Ltd","Research Division","Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Chugai Pharmaceutical Co., Ltd","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Research Division","institution_ids":[]},{"raw_affiliation_string":"Tokyo, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Hitoshi Katada","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hitoshi Katada","raw_affiliation_strings":["Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","Chugai Pharmaceutical Co., Ltd","Research Division","Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Chugai Pharmaceutical Co., Ltd","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Research Division","institution_ids":[]},{"raw_affiliation_string":"Tokyo, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007255434","display_name":"Shojiro Kadono","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Shojiro Kadono","raw_affiliation_strings":["Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","Chugai Pharmaceutical Co., Ltd","Research Division","Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Chugai Pharmaceutical Co., Ltd","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Research Division","institution_ids":[]},{"raw_affiliation_string":"Tokyo, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020139752","display_name":"Takayuki Kamikawa","orcid":"https://orcid.org/0009-0008-6118-3871","observed_orcids":["https://orcid.org/0009-0008-6118-3871"]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Takayuki Kamikawa","raw_affiliation_strings":["Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","Chugai Pharmaceutical Co., Ltd","Research Division","Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Chugai Pharmaceutical Co., Ltd","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Research Division","institution_ids":[]},{"raw_affiliation_string":"Tokyo, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076646553","display_name":"Meiri Shida-Kawazoe","orcid":"https://orcid.org/0009-0007-9659-3486","observed_orcids":["https://orcid.org/0009-0007-9659-3486"]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Meiri Shida-Kawazoe","raw_affiliation_strings":["Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","Chugai Pharmaceutical Co., Ltd","Research Division","Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Chugai Pharmaceutical Co., Ltd","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Research Division","institution_ids":[]},{"raw_affiliation_string":"Tokyo, Japan","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5013907733","display_name":"Kunihiro Hattori","orcid":"https://orcid.org/0009-0008-2707-1147","observed_orcids":["https://orcid.org/0009-0008-2707-1147"]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kunihiro Hattori","raw_affiliation_strings":["Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","Chugai Pharmaceutical Co., Ltd","Research Division","Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo, Japan","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Chugai Pharmaceutical Co., Ltd","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Research Division","institution_ids":[]},{"raw_affiliation_string":"Tokyo, Japan","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5005341632"],"corresponding_institution_ids":["https://openalex.org/I4405254473"],"apc_list":{"value":2915,"currency":"GBP","value_usd":3575},"apc_paid":{"value":2915,"currency":"GBP","value_usd":3575},"fwci":2.4985,"has_fulltext":true,"cited_by_count":80,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.8909629,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"5","issue":"2","first_page":"229","last_page":"236"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11124","display_name":"Protein purification and stability","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fc-engineering","display_name":"Fc engineering","score":0.8650000095367432},{"id":"https://openalex.org/keywords/fcgammar-binding","display_name":"Fc\u03b3R binding","score":0.8119999766349792},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.9010000228881836},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.6790000200271606},{"id":"https://openalex.org/keywords/effector-function","display_name":"effector function","score":0.7170000076293945},{"id":"https://openalex.org/keywords/therapeutic-antibodies","display_name":"therapeutic antibodies","score":0.5839999914169312}],"concepts":[{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.9555023908615112},{"id":"https://openalex.org/C125823703","wikidata":"https://www.wikidata.org/wiki/Q1616930","display_name":"Fragment crystallizable region","level":3,"score":0.7580075263977051},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.6897761821746826},{"id":"https://openalex.org/C147816474","wikidata":"https://www.wikidata.org/wiki/Q169525","display_name":"Protein engineering","level":3,"score":0.5923082828521729},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5918091535568237},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5912091135978699},{"id":"https://openalex.org/C51785407","wikidata":"https://www.wikidata.org/wiki/Q2627568","display_name":"Effector","level":2,"score":0.5355716943740845},{"id":"https://openalex.org/C2909900342","wikidata":"https://www.wikidata.org/wiki/Q1616930","display_name":"Immunoglobulin Fc Fragments","level":4,"score":0.48505204916000366},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.43684515357017517},{"id":"https://openalex.org/C2779931124","wikidata":"https://www.wikidata.org/wiki/Q417823","display_name":"Fc receptor","level":3,"score":0.4350922107696533},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.40464553236961365},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3968926668167114},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.3839956521987915},{"id":"https://openalex.org/C2780898057","wikidata":"https://www.wikidata.org/wiki/Q79448","display_name":"Immunoglobulin G","level":3,"score":0.313579261302948},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.22562551498413086},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2124796211719513},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1953878402709961},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D000915","descriptor_name":"Antibody Affinity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000918","descriptor_name":"Antibody Specificity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000920","descriptor_name":"Antibody-Dependent Cell Cytotoxicity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002460","descriptor_name":"Cell Line","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005643","descriptor_name":"Fucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014644","descriptor_name":"Genetic Variation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015202","descriptor_name":"Protein Engineering","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D017452","descriptor_name":"Receptors, IgG","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D019943","descriptor_name":"Amino Acid Substitution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.4161/mabs.23452","doi":"https://doi.org/10.4161/mabs.23452","is_oa":true,"landing_page_url":"https://doi.org/10.4161/mabs.23452","pdf_url":"https://www.tandfonline.com/doi/pdf/10.4161/mabs.23452?needAccess=true","source":{"id":"https://openalex.org/S169123381","display_name":"mAbs","issn_l":"1942-0862","issn":["1942-0862","1942-0870"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315740","host_organization_name":"Landes Bioscience","host_organization_lineage":["https://openalex.org/P4310315740"],"host_organization_lineage_names":["Landes Bioscience"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"mAbs","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:3893233","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3893233/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3893233/pdf/","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"MAbs","raw_type":"Text"},{"id":"pmh:oai:europepmc.org:2887797","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC3893233","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmid:23406628","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23406628","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"mAbs","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.4161/mabs.23452","doi":"https://doi.org/10.4161/mabs.23452","is_oa":true,"landing_page_url":"https://doi.org/10.4161/mabs.23452","pdf_url":"https://www.tandfonline.com/doi/pdf/10.4161/mabs.23452?needAccess=true","source":{"id":"https://openalex.org/S169123381","display_name":"mAbs","issn_l":"1942-0862","issn":["1942-0862","1942-0870"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315740","host_organization_name":"Landes Bioscience","host_organization_lineage":["https://openalex.org/P4310315740"],"host_organization_lineage_names":["Landes Bioscience"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"mAbs","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8048999905586243,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320333003","display_name":"Chugai Pharmaceutical","ror":"https://ror.org/01vepzj85"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2051652916.pdf","grobid_xml":"https://content.openalex.org/works/W2051652916.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W1529809181","https://openalex.org/W1898709442","https://openalex.org/W1965962344","https://openalex.org/W1966286047","https://openalex.org/W1968924601","https://openalex.org/W1969824500","https://openalex.org/W1971538318","https://openalex.org/W1973718144","https://openalex.org/W1992966594","https://openalex.org/W2033439473","https://openalex.org/W2037007095","https://openalex.org/W2044360617","https://openalex.org/W2057745345","https://openalex.org/W2084136419","https://openalex.org/W2086542713","https://openalex.org/W2100612316","https://openalex.org/W2111262648","https://openalex.org/W2111728443","https://openalex.org/W2115175735","https://openalex.org/W2120323942","https://openalex.org/W2127214162","https://openalex.org/W2128402413","https://openalex.org/W2137354517","https://openalex.org/W2143562636","https://openalex.org/W2159840467","https://openalex.org/W2168313542"],"related_works":["https://openalex.org/W2036609771","https://openalex.org/W2107644060","https://openalex.org/W4206390344","https://openalex.org/W2804801043","https://openalex.org/W2143562636","https://openalex.org/W2892240690","https://openalex.org/W2592845175","https://openalex.org/W2038876401","https://openalex.org/W2394525831","https://openalex.org/W2146146606"],"abstract_inverted_index":{"Fc":[0,75,90,99,123,145,160,166,197],"engineering":[1,23,91,167,198],"is":[2],"a":[3,88],"promising":[4],"approach":[5,92,168],"to":[6,27,46,56,106,110],"enhance":[7,28],"the":[8,36,50,63,68,111,116,126,135,164,174,180,183,188,195],"antitumor":[9],"efficacy":[10],"of":[11,34,38,52,67,176,182],"monoclonal":[12],"antibodies":[13,206],"(mAbs)":[14],"through":[15],"antibody-dependent":[16],"cell-mediated":[17],"cytotoxicity":[18],"(ADCC).":[19],"Glyco-":[20],"and":[21,31,108,134,147],"protein-Fc":[22],"have":[24],"been":[25,78],"employed":[26],"Fc\u03b3R":[29,54,58,107,113],"binding":[30,44,55,59,104,128],"ADCC":[32,155],"activity":[33,156],"mAbs;":[35],"drawbacks":[37],"previous":[39],"approaches":[40],"lie":[41],"in":[42,97,153],"their":[43],"affinity":[45,105,129],"both":[47,131],"Fc\u03b3RIIIa":[48,132],"allotypes,":[49],"ratio":[51,138],"activating":[53,112],"inhibitory":[57],"(A/I":[60],"ratio)":[61],"or":[62,149],"melting":[64],"temperature":[65],"(T(M))":[66],"C(H)2":[69,184],"domain.":[70],"To":[71],"date,":[72],"no":[73],"engineered":[74,144],"variant":[76,124],"has":[77],"reported":[79,142],"that":[80,93,178,194],"satisfies":[81],"all":[82],"these":[83],"points.":[84],"Herein,":[85],"we":[86],"present":[87],"novel":[89],"introduces":[94],"different":[95],"substitutions":[96,177],"each":[98],"domain":[100,185],"asymmetrically,":[101],"conferring":[102],"optimal":[103],"specificity":[109],"without":[114],"impairing":[115],"stability.":[117],"We":[118],"successfully":[119],"designed":[120],"an":[121],"asymmetric":[122,165,196],"with":[125,140,158,187],"highest":[127,136],"for":[130,204],"allotypes":[133],"A/I":[137],"compared":[139,157,186],"previously":[141],"symmetrically":[143],"variants,":[146],"superior":[148],"at":[150],"least":[151],"comparable":[152],"vitro":[154],"afucosylated":[159],"variants.":[161],"In":[162],"addition,":[163],"offered":[169],"higher":[170],"stability":[171],"by":[172],"minimizing":[173],"use":[175],"reduce":[179],"T(M)":[181],"symmetric":[189],"approach.":[190],"These":[191],"results":[192],"demonstrate":[193],"platform":[199],"provides":[200],"best-in-class":[201],"effector":[202],"function":[203],"therapeutic":[205],"against":[207],"tumor":[208],"antigens.":[209]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2051652916","counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":10},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":3}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
